Retinopathy of prematurity incidence and treatment modalities in moderate and late preterm infants: a study from two tertiary centers

ÇÖMEZ, AYŞEGÜL; Celemler, Pelin; ÖZMEN, MEHMET; YURTTUTAN, SADIK; Akkececi, Nurten; Gungor, Kivanc; Saygili, Oguzhan

doi:10.1016/j.jcjo.2021.03.014

Retinopathy of prematurity incidence and treatment modalities in moderate and late preterm infants: a study from two tertiary centers

Atıf İçin Kopyala

ÇÖMEZ A., Celemler P., ÖZMEN M. C., YURTTUTAN S., Akkececi N. S., Gungor K., ...Daha Fazla

CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, cilt.57, sa.3, ss.195-200, 2022 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 57 Sayı: 3
Basım Tarihi: 2022
Doi Numarası: 10.1016/j.jcjo.2021.03.014
Dergi Adı: CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
Sayfa Sayıları: ss.195-200
Gazi Üniversitesi Adresli: Evet

Özet

Objective: The aim of this study was to evaluate the incidence, severity, and treatment modalities of retinopathy of prematurity (ROP) in moderate and late preterm infants with a gestational age (GA) 0.001 for all). Of 102 patients (2.5%) requiring treatment, 64 (62.7%) had laser, 34 (33.3%) had intravitreal bevacizumab (IVB), 2 (1.9%) had sequential IVB and laser, and 2 (1.9%) had vitreoretinal surgery. Conclusion: ROP seems to still be an important health problem in moderate and late preterm infants in our country according to data from screening high-risk preterm infants with a GA 31 +6 weeks. In this cohort, ROP development correlates with GA, BW, and duration of hospitalization significantly.